delivers

medicine

Loss of funding means closure for maternity clinic which delivers half of Medicine Hat’s babies

A maternity clinic that delivers about half the babies in Medicine Hat has announced it will no longer accept new patients by the end of January, and will be closed by the end of July unless new funding can be found.

While family physicians typically pay their own overhead, a gap in Medicine Hat’s obstetric services in the mid-2000s led to the creation of the Family Medicine Maternity Clinic.

Funding was provided by the local Primary Care Network (PCN) and Palliser Health, which later merged with the other regional health authorities to form Alberta Health Services. 

Dr. Gerry Prince, a family doctor who helped establish the clinic in 2006, told the Calgary Eyeopener on Monday that the clinic will be closing because the PCN’s funding is due to end in March, and AHS wants the clinic to cover the overhead that includes rent, utilities and all staffing costs.

Prince said this would be impossible, as the costs to run the maternity clinic are roughly double the amount of what it can bill for patient services — and the doctors are already paying overhead for their family practices. 

“[The clinic] is closing because AHS is backing out of our partnership, and says that they want to rent us the space that we’ve been able to occupy for the last 17 years with their support,” Prince said.

“And the numbers they’ve given us are just impossible. So, they’ve given us an overhead number, which is about double the amount of billing that we would actually do through the clinic in a year.… Our guys, you know, as much as they love it, just — there’s no way you can do that.”

A ‘flawless service’

The Family Medicine Maternity Clinic was established due to a crisis of accessibility, Prince said. At the time, obstetrics was a declining service in the area.

“There [were] fewer and fewer physicians doing it, and got down to the point where there were only two family docs delivering about half of the babies in town — as well as running the regular community clinic,” Prince said.

“It was becoming quickly unmanageable.”

Prince said that some of the local doctors turned to health authorities and asked for help. 

The regional health authority agreed, and later partnered with the Primary Care Network to meet the community need. The clinic was established, attached to the Medicine Hat Regional Hospital.

“We went with this idea of a maternity clinic, a dedicated care centre, and they helped support it. And ultimately, we built a specified, designated, custom-design clinic area in our new ambulatory care building,” Prince said.

Eventually, Prince said, that clinic would deliver 500 to 600 babies a year.

“We’ve had a flawless service that’s been providing great care for 17 years.”

Soon, it’s all coming to an end — and why is complicated.

“The docs want to provide the services, we just need to be able to manage it financially. So the real question is, whose job is it [to save

Read More
health

Pfizer delivers final blow to Trump’s hope for preelection vaccine

There won’t be a coronavirus vaccine ready before Election Day, despite President Donald Trump’s repeated promises and vaccine makers’ breakneck speed.

The president’s last best hope for meeting that deadline fizzled Friday as Pfizer announced that it would not seek emergency authorization from the Food and Drug Administration before the third week of November. The company is the only frontrunner in the vaccine race that has said it could have proof its vaccine works by Nov. 3.

For Trump, the failure to meet that deadline is a self-inflicted defeat. The Election Day target was always an artificial one, created by a president who for months has touted it on the campaign trail and press briefing stage. When his administration’s top scientists disputed the timeline, Trump accused them of slowing down progress for political reasons.

In the meantime, dozens of companies, universities and government agencies are working at record speed — cutting years off the normal development process to deliver a vaccine for the virus that has killed nearly 220,000 people in the U.S. and 1 million worldwide. That historic push is still on track to deliver a vaccine by early 2021, roughly a year after the virus first emerged.

“It was never going to happen. It was utterly unrealistic,” said Lawrence Gostin, director of the WHO Collaborating Center on National and Global Health Law at Georgetown University. “Vaccines follow a timeline of good science, they don’t follow a timeline of electoral politics.”

Since the beginning of the pandemic, federal health officials including infectious disease expert Anthony Fauci, CDC Director Robert Redfield and Health and Human Services Secretary Alex Azar have said that a vaccine is most likely by the end of the year or early 2021.

But those projections have always been riddled with caveats. Enrollment in clinical trials to test the shots’ safety and efficacy does not always proceed as quickly as companies would like. Too few people in those trials may be exposed to the virus, delaying the collection of crucial data. And the studies may find that a vaccine is dangerous — or simply doesn’t work.

“Nature is hard. You can’t use your political rhetoric to bamboozle nature,” said Ezekiel Emanuel, chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania and an adviser to Democratic presidential candidate Joe Biden. Emanuel penned a letter to Pfizer this month with dozens of scientists raising concerns about speeding the vaccine before safety data was clear.

Two manufacturers, AstraZeneca and Johnson & Johnson, recently paused clinical trials after each reported a serious illness in their studies. While J&J only halted the trials this week, AstraZeneca still has not resumed U.S. studies that stopped in September.

Executives at Moderna, another frontrunner whose vaccine relies on a still-unproven technology, has said it will not be ready to submit an emergency authorization application to FDA until late November. Pfizer, meanwhile, continues to expand its trial — first to enroll thousands more adults, and most recently to

Read More
health

Pfizer delivers final blow to Trump’s hope for pre-election vaccine

Executives at Moderna, another frontrunner whose vaccine relies on a still-unproven technology, has said it will not be ready to submit an emergency authorization application to FDA until late November. Pfizer, meanwhile, continues to expand its trial — first to enroll thousands more adults, and most recently to include teens. Those moves could further push back its timeline, because the FDA expects companies applying for emergency authorization to submit two months of data on at least half of trial participants.

“Just because we are waiting until the end of the year instead of October — just to keep things in perspective, this is still a land speed record for vaccines,” said Peter Hotez, a virologist and dean of the National School of Tropical Medicine at the Baylor College of Medicine. Hotez has worked on several shots including a potential SARS vaccine, each of which has taken years if not decades of work to develop and test.

But the rapid pace of coronavirus shot development thus far hasn’t satisfied Trump, whose administration has put the quest for a vaccine at the center of its pandemic response efforts.

“We’ll have the vaccine soon, maybe before a special date. You know what date I’m talking about,” he said in an early September news conference. When FDA pushed to beef up its standards for authorizing emergency use of coronavirus vaccines, he called it “a political move more than anything else.”

The agency revised its guidance to make sure drug makers submitted enough data to reveal any side effects from their shots, Hotez said. It “wasn’t done to punish the president, it was done to protect the public to ensure that we have vaccines that work and are safe,” he said.

As vaccine timelines turned hazy, Trump turned his attentions to drugs known as monoclonal anitbodies. He declared an experimental antibody by drug a “cure” earlier this month, after receiving the treatment during his hospitalization for Covid-19. The president has repeatedly promised the cocktails will soon be available to every American who needs them.

Yet within a week of his initial promise, Eli Lilly — the other company with an antibody drug in late-stage clinical trials — paused its studies over safety concerns.

The bumps on the road to a vaccine or an antibody drug leave health officials with tools that Trump and other White House officials have long questioned: mask-wearing, social distancing and widespread testing.

Trump’s antibody rhetoric “was a pivot when it was clear that the vaccines weren’t going to fill his timeline. And its quite clear that the antibodies aren’t going to fill his timeline either,” said Emanuel.

But the longer timeline for vaccines could help public confidence in an eventual shot. Most registered voters want manufacturers to fully test vaccines even if it delays delivering the shots to Americans, according to a recent POLITICO/Morning Consult poll.

Nearly half of those voters, across party affiliations, said they believe Trump is pressuring FDA to deliver shots sooner and 35 percent believe it will

Read More